The Kilani Group, a key player in healthcare in Tunisia, has officially concluded a major partnership with the global giant Sanofi.
This alliance aims to ensure the continuity of Sanofi’s activities in the country while strengthening the nation’s industrial autonomy.
To meet the requirements of this partnership, the Kilani Group is mobilizing its expertise through two of its key subsidiaries, thus covering the entire pharmaceutical value chain:
The subsidiary Teriak will take charge of the local manufacturing of a broad portfolio of Sanofi medicines. This transfer of know-how guarantees production to international standards, “Made in Tunisia.”
The subsidiary MEDICIS SARL will be responsible for providing medical information, managing interactions with health authorities, and conducting scientific promotion among healthcare professionals.
Beyond the commercial aspect, this collaboration is part of a public health vision. The objective is clear: to guarantee Tunisian patients sustainable access to high-quality treatments.
“This step reflects our long-standing commitment to supporting a robust healthcare system and fostering the introduction of therapeutic innovations tailored to Tunisia’s needs,” states the group’s management.
With its 2,900 employees and widely recognized industrial expertise, the Kilani Group confirms its leadership position. By supporting Sanofi in this strategic evolution, the group demonstrates its ability to manage complex medicine portfolios and attract major technological investments.
This partnership marks a new era for the Tunisian pharmaceutical sector, placing health sovereignty and innovation at the heart of national priorities.
